menu
    • menu

    Company profile for Alzamend Neuro

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alzamend Neuro™ (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company ...
    Alzamend Neuro™ (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company is providing hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alzamend NeuroUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3802 Spectrum Blvd #112c, Tampa, FL 33612
    Telephone
    Telephone
    +1 844-722-6333
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alzamend.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AlzamendNeuro

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzamend AL001 Shows Bioequivalence, Better Brain Delivery
    Alzamend AL001 Shows Bioequivalence, Better Brain Delivery

    26 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions-302725991.html

    PR NEWSWIRE
    26 Mar 2026
    Share Share
    Alzamend Neuro Starts Phase 2 Trial Of AL001 For Bipolar Disorder
    Alzamend Neuro Starts Phase 2 Trial Of AL001 For Bipolar Disorder

    16 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-patients-with-bipolar-disorder-in-collaboration-with-massachusetts-general-hospital-302714440.html

    PR NEWSWIRE
    16 Mar 2026
    Share Share
    Alzamend Neuro to Speak at 2025 Military Health Symposium
    Alzamend Neuro to Speak at 2025 Military Health Symposium

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122431/0/en/Alzamend-Neuro-to-Present-at-the-2025-Military-Health-System-Research-Symposium.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    Alzamend Neuro's 2025 Financial Results and Program Updates
    Alzamend Neuro's 2025 Financial Results and Program Updates

    23 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/23/3120190/0/en/Alzamend-Neuro-Reports-Annual-2025-Financial-Results-and-Provides-Update-on-Clinical-Programs.html

    GLOBENEWSWIRE
    23 Jul 2025
    Share Share
    Alzamend Neuro Closes $5M Private Placement Early
    Alzamend Neuro Closes $5M Private Placement Early

    16 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/16/3099775/0/en/Alzamend-Neuro-Announces-Final-Closing-of-5-Million-Private-Placement-Months-Ahead-of-Schedule.html

    GLOBENEWSWIRE
    16 Jun 2025
    Share Share
    Alzamend Doses First Patient in Ph 2 Brain Lithium Study
    Alzamend Doses First Patient in Ph 2 Brain Lithium Study

    29 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/29/3090267/0/en/Alzamend-Neuro-Announces-Dosing-of-First-Patient-in-its-Phase-II-Clinical-Trial-of-AL001-Lithium-in-Brain-Study-Taking-Place-at-Massachusetts-General-Hospital.html

    GLOBENEWSWIRE
    29 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search